1 Min Read
Dec 5 (Reuters) - Oncodesign Sa:
* PROGRAM HAS IDENTIFIED INHIBITORY MOLECULES WITH HIGH SPECIFICITY
* PROMISING CELLULAR RESULTS ALLOWING A TRANSITION TO LEAD OPTIMIZATION PHASE Source text for Eikon: Further company coverage: (Gdynia Newsroom)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.